Table 1

Summary of additional medication, clinical and serologic characteristics of the analyzed lupus patients

AZA

MMF

No IS

n = 30

%

n = 39

%

n = 38

%


Medication a

Prednisone

26

87

38

97

14

37

mg/day, median (range)

5.0 (0-50) §§§

5.0 (0-30)###

0 (0-20)§§§ ###

Hydroxychloroquine

17

57

26

67

29

76

Manifestations a

Nephritis

20

67

35

90

13

34

Proliferative class III, IV of all biopsy results available

12

75

22

76

3

38

CRF grade III+

5

25

6

17

1

8

Nephritis in remission

9

45

20

57

7

58

Active nephritis

11

55

15

43

6

46

New nephritis

1

5

0

0

6

46

Arthritis

3

10

2

5

9

24

Serositis

1

3

0

0

4

11

Myositis

2

7

1

3

0

0

CNS

1

3

0

0

1

3

Vasculitis

1

3

1

3

1

3

Flaresa

14

47

9

23

12

32

Lupus nephritis flare

10

71

4

44

6

50

CNS flare

0

0

0

0

1

3

Arthritis flare

0

0

2

22

5

42

Serositis flare

2

14

0

0

3

8

Myositis flare

1

7

1

11

0

0

Vasculitis flare

0

0

1

11

0

0

Ref. thrombocytopenia

0

0

1

11

0

0

ILD flare

1

7

0

0

0

0

Autoantibodies a

Anti-dsDNA

27

90

36

92

28

74

C median, U/ml (range)

39 (0-1,250)

29 (0-1,065)

32 (0-1,496)

Anti-Ro

17

57

16

41

24

65

Anti-La

8

27

6

15

10

27

Anti-U1RNP

11

37

14

36

20

54

Anti-SM

6

20

6

15

8

22

APLA/LA

10

33

14

38b

9

28b

Consumption of complement factors a

15

50

16

41

15

39

SLEDAI

Median (range)

6 (0-18)

4 (0-14)

4 (0-24)


Results are presented as number and percent of patients unless otherwise stated. aResulting in an intensification of the immunosuppressive therapy (> 50mg prednisone-equivalent added, or switch of the therapy regimen to a more potent regimen, such as cyclophosphamide). AZA, azathioprine; MMF, mycophenolate mophetil; IS, immunosuppression; CRF, chronic renal failure; CNS, central nervous system; ILD, interstitial lung disease; APLA, anti-phospholipid antibodies; LA, lupus anticoagulant; SLEDAI, SLE disease activity index. bData incomplete (antibody status known in 37 and 32 patients respectively). Statistically significant differences detected between the dose of prednisone-equivalent, Dunn's Multiple Comparison test: #P < 0.05, ##P < 0.01, ###P < 0.001 statistically significant differences between patients taking MMF compared to patients without immunosuppressive therapy (no IS). §P < 0.05, §§P < 0.01, §§§P < 0.001 for statistically significant differences between patients taking AZA compared to patients without immunosuppressive therapy.

Eickenberg et al. Arthritis Research & Therapy 2012 14:R110   doi:10.1186/ar3835

Open Data